[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Wykoff CC, Lam BL, Brathwaite CD, Biegel JA, McKeown CA, Rosenblum MK, Allewelt HB, Sandberg DI: Atypical teratoid/rhabdoid tumor arising from the third cranial nerve. J Neuroophthalmol; 2008 Sep;28(3):207-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical teratoid/rhabdoid tumor arising from the third cranial nerve.
  • An otherwise healthy 6-week-old girl who presented with an isolated left third cranial nerve palsy underwent MRI that revealed an enhancing mass intrinsic to the left third cranial nerve.
  • Rapid enlargement of the lesion over 1 month led to subtotal neurosurgical resection of an atypical teratoid/rhabdoid tumor (AT/RT), a rare, highly aggressive malignancy of infancy closely related histologically to medulloblastoma and primitive neuroectodermal tumor.
  • Despite aggressive chemotherapy, the patient died within 6 months of presentation.
  • This is the first report of an AT/RT presenting as an isolated third cranial nerve palsy caused by tumor arising from within the nerve.

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):503-11 [11585322.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2877-84 [15254056.001]
  • [Cites] Am J Ophthalmol. 1977 Jan;83(1):106-11 [835652.001]
  • [Cites] J Neurooncol. 1995;24(1):21-8 [8523069.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):56-65 [8683283.001]
  • [Cites] Am J Surg Pathol. 2006 Nov;30(11):1462-8 [17063089.001]
  • [Cites] Cancer. 2005 Apr 25;105(2):65-70 [15690353.001]
  • [Cites] Can J Ophthalmol. 2005 Oct;40(5):645-53 [16391633.001]
  • [Cites] Pediatr Radiol. 2006 Feb;36(2):126-32 [16341528.001]
  • [Cites] Neurosurg Focus. 2006;20(1):E11 [16459991.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1083-92 [9737241.001]
  • (PMID = 18769285.001).
  • [ISSN] 1536-5166
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / P30 EY014801; United States / NCI NIH HHS / CA / R01 CA046274; United States / NCI NIH HHS / CA / CA46274; United States / NCI NIH HHS / CA / R01 CA046274-17A2; United States / NEI NIH HHS / EY / P30-EY014801; United States / NCI NIH HHS / CA / CA046274-17A2
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS110134; NLM/ PMC2839362
  •  go-up   go-down


2. Bakoyiannis KC, Georgopoulos SE, Klonaris CN, Tsekouras NS, Felekouras ES, Pikoulis EA, Griniatsos JE, Papalambros EL, Bastounis EA: Surgical treatment of carotid body tumors without embolization. Int Angiol; 2006 Mar;25(1):40-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of carotid body tumors without embolization.
  • AIM: Carotid body (CB) paragangliomas are rare neoplasms, usually benign.
  • This study deals with our 10-year experience in their surgical treatment and the evaluation of its effectiveness, without preoperative embolization.
  • Twelve tumors were surgically resected and no patient underwent preoperative selective embolism of his tumor.
  • No one of the patients underwent radiotherapy or chemotherapy.
  • One patient, with a grade III tumor, had an injury of the internal carotid artery that was repaired with a vein patch.
  • Three patients had temporal cranial nerve lesions that resolved within 3 months.
  • CONCLUSIONS: Early surgical treatment is strongly recommended in almost all patients.
  • Preoperative embolism of the tumor does not need to be a routine procedure.
  • [MeSH-major] Carotid Body Tumor / surgery. Endarterectomy, Carotid
  • [MeSH-minor] Adult. Aged. Angioplasty. Female. Humans. Male. Medical Records. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520723.001).
  • [ISSN] 0392-9590
  • [Journal-full-title] International angiology : a journal of the International Union of Angiology
  • [ISO-abbreviation] Int Angiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


3. Badhe PB, Chauhan PP, Mehta NK: Brainstem gliomas--a clinicopathological study of 45 cases with p53 immunohistochemistry. Indian J Cancer; 2004 Oct-Dec;41(4):170-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The WHO brain tumor classification and Stroink's CT classification were applied.
  • RESULTS AND CONCLUSIONS: 51 % of gliomas were observed in the first decade of life.
  • The commonest presenting features were cranial nerve palsies (33%) and cerebellar signs (29.8%).
  • Grade II astrocytomas were treated with excision and radiotherapy, while grade III and IV tumors were treated with radiotherapy and chemotherapy (CCNU).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Stem Neoplasms / metabolism. Glioma / metabolism. Tumor Suppressor Protein p53 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15659871.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


Advertisement
4. Varma AK, Muller PJ: Cranial neuropathies after intracranial Photofrin-photodynamic therapy for malignant supratentorial gliomas-a report on 3 cases. Surg Neurol; 2008 Aug;70(2):190-3
MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cranial neuropathies after intracranial Photofrin-photodynamic therapy for malignant supratentorial gliomas-a report on 3 cases.
  • BACKGROUND: In an RCT of PDT in the treatment of malignant gliomas, 3 patients developed cranial neuropathies after photoillumination.
  • We are aware of no previous reports on cranial neuropathy after intracranial PDT.
  • All patients underwent surgical tumor extirpation.
  • There were 77 malignant gliomas, 2 meningiomas, and 1 metastatic tumor.
  • The tumor locations were as follows: 39 frontal, 25 temporal, 12 parietal, and 4 occipital.
  • RESULTS: Three of the 18 patients with temporal lobe tumors developed cranial neuropathies after PDT.
  • The first patient developed seventh nerve paresis and hypoesthesia in fifth nerve distribution, which resolved only partially.
  • The second patient developed a seventh nerve paresis that resolved completely.
  • The third patient developed transient neuralgic pain in the trigeminal nerve distribution.
  • CONCLUSIONS: Cranial neuropathies could be the result of photoillumination of fifth and seventh cranial nerves during PDT of the temporal fossa.
  • [MeSH-major] Cranial Nerve Diseases / chemically induced. Dihematoporphyrin Ether / adverse effects. Glioma / drug therapy. Peripheral Nervous System Diseases / chemically induced. Photochemotherapy / adverse effects. Supratentorial Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / adverse effects. Cranial Fossa, Middle / pathology. Facial Nerve / anatomy & histology. Facial Nerve / drug effects. Facial Nerve / physiopathology. Facial Nerve Diseases / chemically induced. Facial Nerve Diseases / metabolism. Facial Nerve Diseases / physiopathology. Female. Humans. Light / adverse effects. Male. Middle Aged. Photic Stimulation / adverse effects. Preoperative Care / standards. Temporal Lobe / pathology. Temporal Lobe / physiopathology. Trigeminal Nerve / anatomy & histology. Trigeminal Nerve / drug effects. Trigeminal Nerve / physiopathology. Trigeminal Nerve Diseases / chemically induced. Trigeminal Nerve Diseases / metabolism. Trigeminal Nerve Diseases / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17976702.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


5. Beauchesne P, Mosnier JF, Schmitt T, Brunon J: Malignant nerve sheath tumor of the right cerebral peduncle: case report. Neurosurgery; 2004 Feb;54(2):500-3; discussion 503-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant nerve sheath tumor of the right cerebral peduncle: case report.
  • Primary malignant intracerebral nerve sheath tumors are extremely rare, with only five documented cases in the international literature.
  • We report one case of a primary malignant intracerebral nerve sheath tumor occurring in the right cerebral peduncle of a 35-year-old man.
  • INTERVENTION: Unlike the five cases previously reported, this is the first time a stereotactic biopsy has been performed, and this is the only patient who responded to cranial radiation therapy for approximately 2 years.
  • When the tumor recurred, a systemic chemotherapy treatment was prescribed.
  • No positive response was seen, and the patient died 29 months after the initial diagnosis.
  • CONCLUSION: An accurate diagnosis and planned aggressive treatment seem to be the key elements in the management of the disease.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Mesencephalon / pathology. Myelin Sheath / pathology. Neurilemmoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14744297.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Johnson TE, Toledano SR: Ganglioneuroblastoma metastatic to the orbit. Ophthal Plast Reconstr Surg; 2003 Jul;19(4):330-3
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 10-month-old girl presented with an extensive orbital and cranial metastatic lesion from an adrenal ganglioneuroblastoma.
  • Treatment with chemotherapy alone resulted in complete regression of the tumors with over 7 years of follow-up.
  • Good prognostic indicators included her young age at diagnosis, DNA index of tumor cells of 1.4, and the histologic subtype of neuroblastic tumor.
  • This is the first reported case of ganglioneuroblastoma metastatic to the orbit.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Ganglioneuroblastoma / secondary. Orbital Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Female. Humans. Infant. Nerve Tissue Proteins / analysis. Skull Neoplasms / diagnosis. Skull Neoplasms / drug therapy. Skull Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12878887.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Nerve Tissue Proteins
  •  go-up   go-down


7. Koh EJ, Phi JH, Park SH, Kim IO, Cheon JE, Wang KC, Cho BK, Kim SK: Mixed germ cell tumor of the midbrain. Case Report. J Neurosurg Pediatr; 2009 Aug;4(2):137-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed germ cell tumor of the midbrain. Case Report.
  • This 14-year-old boy presented with left hemiparesis, gait disturbance, and multiple cranial nerve palsies.
  • Diffusion tensor imaging showed the mass to be close to the right corticospinal tract and ipsilateral medial lemniscus.
  • The histopathological diagnosis was of a mixed germ cell tumor (GCT) comprising mature teratoma and germinoma cells with syncytiotrophoblastic giant cells.
  • The patient underwent postoperative chemotherapy and radiotherapy, and no tumor progression was found during 1 year of follow-up.
  • To the authors' knowledge, this is the first reported case of a mixed GCT in the midbrain combining mature teratoma and germinoma cells.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Brain Stem Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645547.001).
  • [ISSN] 1933-0707
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Sinnott BP, Hatipoglu B, Sarne DH: Intrasellar plasmacytoma presenting as a non-functional invasive pituitary macro-adenoma: case report & literature review. Pituitary; 2006;9(1):65-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report an uncommon case of an intrasellar plasmacytoma presenting as a non-functional invasive pituitary macro-adenoma as the first manifestation of multiple myeloma.
  • A 57 year old woman was referred to our department with a presumed diagnosis of a non-functioning pituitary macro-adenoma.
  • A diagnosis of multiple myeloma was made 1 month later based on a combination of clinical, pathological and radiologic features.
  • She underwent radiation therapy directed towards the residual sellar tumor, followed by chemotherapy and autologous stem cell transplantation.
  • Review of the world literature revealed only 22 previous reports of patients in whom a solitary plasmacytoma or multiple myeloma first presented as a sellar mass; in all cases mimicking clinically and radiologically a non-functioning invasive pituitary adenoma however with additional cranial nerve involvement.
  • The diagnosis should be suspected in patients with well preserved anterior pituitary function and cranial nerve neuropathies in the presence of significant sellar destruction.
  • [MeSH-major] Adenoma / diagnosis. Pituitary Neoplasms / diagnosis. Plasmacytoma / diagnosis. Plasmacytoma / surgery
  • [MeSH-minor] Deamino Arginine Vasopressin / therapeutic use. Diabetes Insipidus / drug therapy. Diabetes Insipidus / etiology. Diagnosis, Differential. Female. Humans. Middle Aged. Postoperative Complications. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Apr;13(4):653-4 [3558056.001]
  • [Cites] Br J Neurosurg. 2003 Jun;17(3):260-2 [14565527.001]
  • [Cites] Surg Neurol. 1992 May;37(5):388-93 [1631767.001]
  • [Cites] Arch Neurol. 1982 Nov;39(11):738 [7126006.001]
  • [Cites] Brain. 1954;77(1):61-81 [13160259.001]
  • [Cites] Tumori. 2001 Nov-Dec;87(6):451-4 [11989605.001]
  • [Cites] Comput Radiol. 1986 Jul-Aug;10(4):201-5 [3791987.001]
  • [Cites] Med Clin (Barc). 1982 Nov 1-15;79(8):377-9 [6816996.001]
  • [Cites] Arch Neurol. 1963 Nov;9:534-44 [14057685.001]
  • [Cites] J Clin Neurosci. 2002 Sep;9(5):586-9 [12383423.001]
  • [Cites] Lancet. 1967 Dec 23;2(7530):1354-6 [4170040.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):218-21 [7616264.001]
  • [Cites] Postgrad Med J. 1985 Jun;61(716):513-4 [4011536.001]
  • [Cites] Cancer. 1979 Apr;43(4):1513-5 [445346.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jan;101(1):55-6 [576202.001]
  • [Cites] Surg Neurol. 1980 Sep;14(3):233-6 [7001658.001]
  • [Cites] Bull Soc Ophtalmol Fr. 1981 Mar;81(3):355-6 [7226412.001]
  • [Cites] Pathol Oncol Res. 2003;9(2):134-7 [12858221.001]
  • [Cites] Australas Radiol. 2001 May;45(2):244-6 [11380375.001]
  • [Cites] Exp Clin Endocrinol. 1993;101(5):283-9 [8299704.001]
  • [Cites] J Neuroophthalmol. 1996 Sep;16(3):199-203 [8865015.001]
  • [Cites] Arch Neurol. 1992 May;49(5):555-8 [1580820.001]
  • [Cites] Endocr Pract. 1998 Nov-Dec;4(6):382-6 [15251713.001]
  • [Cites] Ital J Neurol Sci. 1994 Oct;15(7):369-72 [7698896.001]
  • [Cites] Rinsho Ketsueki. 1996 Mar;37(3):260-4 [8727353.001]
  • [Cites] Neurol Neurochir Pol. 1991 Sep-Oct;25(5):683-8 [1808532.001]
  • [Cites] Neurochirurgie. 1991;37(1):67-71 [2017297.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Aug;47(4):230-4 [15346320.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1984 Jan;47(1):99-100 [6693924.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3455-9 [8855784.001]
  • [Cites] N Engl J Med. 2004 Dec 16;351(25):2637-45 [15602025.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1201-3 [9298068.001]
  • [Cites] Pituitary. 2004;7(3):179-181 [16328566.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(2):219-20 [10189508.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1513-7 [1540888.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] Br J Neurosurg. 1991;5(4):405-7 [1786137.001]
  • [Cites] No Shinkei Geka. 2001 Jun;29(6):551-7 [11452502.001]
  • (PMID = 16703411.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] ENR1LLB0FP / Deamino Arginine Vasopressin
  • [Number-of-references] 42
  •  go-up   go-down


9. Fukai J, Nohgawa M, Uematsu Y, Itakura T, Kamei I: Immunoglobulin D multiple myeloma involving the sella manifesting as oculomotor palsy: case report. Neurosurgery; 2010 Aug;67(2):E505-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Immunoglobulin D multiple myeloma (IgD MM) is an uncommon type of MM characterized by an aggressive clinical behavior and a short survival time.
  • We report a rare case in which oculomotor palsy caused by a sellar lesion was the initial manifestation of IgD MM; systemic treatments were beneficial in this case.
  • An examination revealed left cranial nerve (CN) III and IV palsies.
  • At the time of admission, the patient had no symptoms of MM.
  • Histopathologic examination revealed a tumor consisting of plasma cells.
  • Appropriate laboratory studies, a bone scan, and a bone marrow biopsy led to a diagnosis of IgD lambda-type MM.
  • High-dose chemotherapy followed by autologous peripheral blood stem cell transplantation was therapeutically beneficial.
  • CONCLUSION: This case demonstrates that an unusual sellar tumor might be the first manifestation of IgD MM.
  • Careful observation can suggest a possible non-pituitary etiology for a tumor, leading to appropriate diagnostic and therapeutic procedures.
  • [MeSH-major] Immunoglobulin D. Multiple Myeloma / therapy. Ophthalmoplegia / etiology. Pituitary Neoplasms / therapy. Sella Turcica / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Blood Protein Electrophoresis. Bone Marrow / pathology. Bone and Bones / pathology. Combined Modality Therapy. Cord Blood Stem Cell Transplantation. Cranial Nerve Diseases / etiology. Cranial Nerve Diseases / pathology. Diplopia / etiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasms, Plasma Cell / surgery. Neurosurgical Procedures. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644379.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin D
  •  go-up   go-down


10. Miyoshi Y, Omori M, Kobayashi N, Masuko T, Watanabe E, Date I: [A case of pineal pure germinoma metastasized to the lumbosacral extradural space 8 years after initial therapy. Case report and review of literature]. No Shinkei Geka; 2006 Jul;34(7):745-52
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pineal pure germinoma metastasized to the lumbosacral extradural space 8 years after initial therapy. Case report and review of literature].
  • An 11-year-old boy first presented with a pineal tumor identified by neuroimaging but without positive serum or cerebrospinal fluid markers.
  • The tumor disappeared after the craniotomy and following cranial irradiation.
  • The pathologic diagnosis of the tumor was of a pure germinoma.
  • Intraoperative findings showed that the spinal tumor was solitarily located in the epidural space.
  • Pathologically the tumor was a pure germinoma metastasis.
  • He was treated by a combination of whole spinal irradiation and chemotherapy.
  • The tumor disappeared after the therapy.
  • Regarding the route of this metastasis, we speculate that the CSF dissemination of the germinoma cells occurred first and some of those cells were trapped in the spinal nerve sleeve and extended into the epidural space.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / secondary. Lumbar Vertebrae / pathology. Pinealoma / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Drug Administration Schedule. Epidural Space. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Laminectomy. Lumbosacral Region / pathology. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Germinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16841711.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; VP-P protocol
  •  go-up   go-down


11. Hashemi M, Stark A, Hugo H, Mehdorn M: Intracranial trigeminal nerve metastasis of a desmoplastic neurotropic melanoma: case report. Cent Eur Neurosurg; 2009 May;70(2):91-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial trigeminal nerve metastasis of a desmoplastic neurotropic melanoma: case report.
  • 4 years previously he underwent tumor removal with an initial diagnosis of amelanotic malignant cutaneous melanoma; 1 year later, because of tumor recurrence, the patient underwent neck dissection, chemotherapy and radiation.
  • Magnet resonance imaging (MRI) disclosed an enhancement of the Gasserian ganglion and tumor extension along the mandibular and maxillar nerves of the intracranial part of the trigeminal nerve suggestive of tumor.
  • The intraoperative macroscopic appearance of the tumor was compatible with a neurinoma.
  • Histopathological studies proved the tumor to be a desmoplastic neurotropic melanoma (DNM) that was related to the previously treated malignant melanoma.
  • CONCLUSION: A metastatic tumor arising solely in a trigeminal nerve from a cutaneous malignant melanoma is quite rare; to our knowledge this may be the first report of such a case in the literature.
  • [MeSH-major] Cranial Nerve Neoplasms / secondary. Melanoma / secondary. Skin Neoplasms / pathology. Trigeminal Nerve. Trigeminal Nerve Diseases / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag KG Stuttgart, New York.
  • (PMID = 19711263.001).
  • [ISSN] 1868-4904
  • [Journal-full-title] Central European neurosurgery
  • [ISO-abbreviation] Cent Eur Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Zhang WC, Zhang L, Wang XD, Wu YS: [Clinical and pathological analysis of malignant carotid body tumor]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Aug;43(8):591-5
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and pathological analysis of malignant carotid body tumor].
  • OBJECTIVE: To summarize the clinical, pathological and prognosis character of malignant carotid body tumor and explore its methods of diagnosis and treatment.
  • METHODS: The data of clinic, pathology, treatment and follow-up of nine patients with malignant carotid body tumor in Tianjin Cancer Hospital from February 1982 to June 2006 were analyzed retrospectively.
  • Shamblin classification: one case was type II, eight cases were type III.
  • Seven cases were diagnosed as carotid body tumor.
  • All the patients were performed wide excision of tumor and surrounding tissue.
  • After operation, eight cases had 13 cranial nerve deficits, they were: two cerchnus, four glossal deviation, three Horner syndrome and one drop of oral corner, one choking cough.
  • Pathologic diagnosis included nine malignant carotid body tumors, two with capsule, seven without capsule, one cervical and one lung metastasis.
  • CONCLUSIONS: Malignant carotid body tumor is rare in clinic, and often invade the carotid and cranial nerve, the diagnosis of malignant tumor should base on occurring extensive invasion of adjacent organs and metastasis; Wide surgical excision should be selected early, radiotherapy is effective, the effect of chemotherapy is uncertainty.
  • [MeSH-major] Carotid Body Tumor / pathology. Carotid Body Tumor / surgery. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery
  • [MeSH-minor] Adult. Cranial Nerves / pathology. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carotid Body Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18959263.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Kobayashi H, Terasaka S, Yamaguchi S, Kubota K, Iwasaki Y: Primary Ewing's sarcoma: peripheral primitive neuroectodermal tumour of the jugular foramen. Acta Neurochir (Wien); 2008 Aug;150(8):817-21
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Ewing's sarcoma: peripheral primitive neuroectodermal tumour of the jugular foramen.
  • We describe an extremely rare example of Ewing's sarcoma (ES)/peripheral primitive neuroectodermal tumour (pPNET) originating from the jugular foramen.
  • The patient was a 10-year-old boy who presented with progressive symptoms due to right lower cranial nerve palsies.
  • Computed tomographic (CT) scan and magnetic resonance imaging (MRI) revealed a tumour at the right jugular foramen which showed extra-cranial extension.
  • Open biopsy of the extra-cranial lesion was performed, and diagnosis of ES/pPNET was made by histopathological, immunohistochemical and genetic investigations.
  • The patient received a combination of multi-drug chemotherapy and irradiation.
  • By 12 months after the diagnosis, MRI showed complete remission of the lesion, and the patient has been well apart from slight dysphagia.
  • Previously, there was only one report of a jugular foramen ES/pPNET and in which treatment had failed.
  • To our best knowledge, this is the first patient treated successfully with chemoradiotherapy.
  • [MeSH-major] Neuroectodermal Tumors, Primitive / diagnosis. Sarcoma, Ewing / diagnosis. Skull Base Neoplasms / diagnosis
  • [MeSH-minor] Antigens, CD / analysis. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biopsy. Cell Adhesion Molecules / analysis. Child. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Diagnosis, Differential. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Phosphopyruvate Hydratase / analysis. Synaptophysin / analysis. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18548190.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Synaptophysin; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; EC 4.2.1.11 / Phosphopyruvate Hydratase; VAC protocol
  •  go-up   go-down


14. Jahraus CD, Tarbell NJ: Optic pathway gliomas. Pediatr Blood Cancer; 2006 May 1;46(5):586-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their propensity to occur in very young children and infants further complicates selection of therapy.
  • Historically, surgery and radiotherapy have played a primary role in management, however, in the last 15 years, chemotherapy has evolved into the first-line treatment of choice.
  • Nonetheless, chemotherapy frequently fails, but serves to delay implementation of radiotherapy or surgery until the child has progressed neuropsychologically.
  • An overall favorable prognosis for this tumor emphasizes the need for careful selection of therapy.
  • Herein, we review the major features of optic pathway glioma, including epidemiology, pathology, therapeutic interventions, outcome, and treatment sequelae.
  • [MeSH-major] Cranial Nerve Neoplasms. Optic Nerve Glioma
  • [MeSH-minor] Combined Modality Therapy. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16411210.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 110
  •  go-up   go-down


15. Leonetti JP, Shirazi MA, Marzo S, Anderson D: Neuroendocrine carcinoma of the jugular foramen. Ear Nose Throat J; 2008 Feb;87(2):86, 88-91
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe what might have been the first reported case of a neuroendocrine carcinoma of the jugular foramen.
  • Magnetic resonance imaging revealed a 4-cm left-sided jugular foramen tumor.
  • The patient underwent near-total resection of the tumor.
  • Despite lower cranial nerve preservation, postoperative paralysis of cranial nerves IX and X occurred, and vocal fold medialization was performed 5 days later.
  • The final pathologic diagnosis was neuroendocrine carcinoma.
  • The patient was treated with concurrent chemotherapy and intensity-modulated radiation therapy.
  • This article will discuss the pathologic features and the management of jugular foramen tumors, along with the differential diagnosis of these rare tumors.
  • [MeSH-major] Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / therapy. Jugular Veins. Skull Base Neoplasms / diagnosis. Skull Base Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ataxia / etiology. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Diagnosis, Differential. Etoposide / therapeutic use. Female. Headache / etiology. Hearing Loss, Sensorineural / etiology. Humans. Magnetic Resonance Imaging. Middle Aged. Radiotherapy, Adjuvant. Radiotherapy, Intensity-Modulated. Tinnitus / etiology. Vertigo / etiology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437928.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Beriat GK, Ezerarslan H, Kocatürk S, Özyar E: [Isolated hypoglossal nerve paralysis: a case report]. Kulak Burun Bogaz Ihtis Derg; 2010 Jul-Aug;20(4):205-9
Genetic Alliance. consumer health - paralysis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Isolated hypoglossal nerve paralysis: a case report].
  • Cranial nerve paralysis is an uncommon complication of radiotherapy for head and neck carcinomas because cranial nerves are relatively resistant to radiation.
  • Unlike the other cranial nerves, isolated hypoglossal nerve paralysis in patients who have been treated with radiotherapy for nasopharyngeal carcinomas is a worrisome sign of recurrence.
  • We report a 45-year-old male patient admitted to our clinics with complaints of difficulty in moving his tongue and dysphasia five years after combined radiotherapy and chemotherapy for nasopharyngeal carcinoma.
  • Recurrence of the tumor was thought to be the cause of the isolated hypoglossal nerve paralysis at first, however late toxicity of radiotherapy was found to be the etiological factor after detailed examinations.
  • [MeSH-major] Hypoglossal Nerve Diseases / pathology. Nasopharyngeal Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiation Injuries / etiology. Radiation Injuries / pathology. Radiotherapy / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20626330.001).
  • [ISSN] 1300-7475
  • [Journal-full-title] Kulak burun boğaz ihtisas dergisi : KBB = Journal of ear, nose, and throat
  • [ISO-abbreviation] Kulak Burun Bogaz Ihtis Derg
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


17. Chang JT, See LC, Liao CT, Ng SH, Wang CH, Chen IH, Tsang NM, Tseng CK, Tang SG, Hong JH: Locally recurrent nasopharyngeal carcinoma. Radiother Oncol; 2000 Feb;54(2):135-42
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: From 1982 to 1995, 186 NPC patients, who had initially been treated in the Department of Radiation Oncology, Chang Gung Memorial Hospital-Linkou, developed local recurrence in the nasopharynx and were re-treated with RT (>/=20 Gy).
  • The time from the initial RT to re-treatment ranged from 8 to 136 months (median: 23 months).
  • Fifteen received radiosurgery as a boost treatment.
  • The RT dose at the nasopharyngeal tumor area ranged from 20 to 67.2 Gy (median 50 Gy).
  • Eighty-two patients received one to eight courses of cisplatin-based chemotherapy in addition to RT.
  • Patients whose tumor relapsed later than 2 years after the first treatment had a better survival than those with earlier relapse (3-year survival: 30.1 vs. 10.8%; P=0.015), but the difference became insignificant in patients who received >/=50 Gy.
  • Patients without evidence of intracranial invasion or cranial nerve palsy had better survival than those with such lesions (3-year survival: 30.9 vs. 3.7%; P=0.006).
  • A re-treatment dose >/=50 Gy yielded better survival (3-year survival: 22.8 vs. 18.5%; P=0.003).
  • The use of chemotherapy did not improve survival.
  • Intracranial invasion and/or cranial nerve palsy and re-treatment dose affect the prognosis, with a dose of >/=50 Gy significantly improving survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Nasopharyngeal Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Radiosurgery. Radiotherapy, Conformal
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10699476.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


18. Hands KE, Alvarez A, Bruder JM: Gonadotropin-releasing hormone agonist-induced pituitary apoplexy in treatment of prostate cancer: case report and review of literature. Endocr Pract; 2007 Oct;13(6):642-6
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gonadotropin-releasing hormone agonist-induced pituitary apoplexy in treatment of prostate cancer: case report and review of literature.
  • OBJECTIVE: To describe a case and review the literature on the rare complication of pituitary apoplexy after administration of a gonadotropin-releasing hormone agonist (GnRHa) for treatment of patients with prostate cancer.
  • Prostate cancer had recently been diagnosed, and he had received his first dose of a GnRHa 4 hours before this presentation.
  • A head computed tomographic scan without contrast enhancement showed soft tissue filling the sella, without intracranial hemorrhage or mass effect.
  • He was discharged with the diagnosis of viral meningitis.
  • He had confusion, lethargy, disorientation, a blood pressure of 88/64 mm Hg, and left cranial nerve III, IV, and VI paralysis.
  • Tumor immunohistochemical staining was positive only for luteinizing hormone.
  • CONCLUSION: We describe a rare adverse effect of GnRHa therapy, which unmasked a gonadotropin-secreting pituitary macroadenoma.
  • [MeSH-major] Gonadotropin-Releasing Hormone / adverse effects. Pituitary Apoplexy / chemically induced. Prostatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pituitary cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954421.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone
  • [Number-of-references] 40
  •  go-up   go-down


19. Kumar S, Das S, Goyal JL, Chauhan D, Sangit V: Bilateral orbital tumor formation and isolated facial palsy in Waldenstrom's macroglobulinemia. Int Ophthalmol; 2005 Dec;26(6):235-7
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral orbital tumor formation and isolated facial palsy in Waldenstrom's macroglobulinemia.
  • A diagnosis of Waldenstrom's macroglobulinemia was made on the basis of these findings.
  • Orbital tumor formation and cranial nerve palsies are rarely reported in this condition.
  • We describe the first case of Waldenstrom's macroglobulinemia presenting as an isolated orbital mass and facial nerve palsy.
  • [MeSH-major] Facial Paralysis / etiology. Orbital Neoplasms / complications. Waldenstrom Macroglobulinemia / complications
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / therapeutic use. Biopsy, Fine-Needle. Chlorambucil / therapeutic use. Diagnosis, Differential. Drug Therapy, Combination. Female. Follow-Up Studies. Glucocorticoids / therapeutic use. Humans. Magnetic Resonance Imaging. Prednisolone / therapeutic use

  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol. 1989 Jun;67(6):689-93 [2500630.001]
  • [Cites] Jpn J Ophthalmol. 1996;40(3):385-9 [8988429.001]
  • [Cites] Surv Ophthalmol. 1981 Nov-Dec;26(3):157-69 [6801795.001]
  • [Cites] Ophthalmologica. 1992;205(1):40-5 [1436990.001]
  • [Cites] Neurology. 1989 Oct;39(10 ):1399 [2507958.001]
  • [Cites] Neurology. 1987 Sep;37(9):1506-14 [2442666.001]
  • [Cites] Ophthalmology. 2000 Jun;107(6):1099-103 [10857829.001]
  • [Cites] Eur J Haematol. 1995 Sep;55(3):205-6 [7672095.001]
  • [Cites] Adv Cancer Res. 1988;51:361-90 [3066147.001]
  • (PMID = 17356930.001).
  • [ISSN] 0165-5701
  • [Journal-full-title] International ophthalmology
  • [ISO-abbreviation] Int Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Glucocorticoids; 18D0SL7309 / Chlorambucil; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


20. Esposito F, Kelly DF, Vinters HV, DeSalles AA, Sercarz J, Gorgulhos AA: Primary sphenoid sinus neoplasms: a report of four cases with common clinical presentation treated with transsphenoidal surgery and adjuvant therapies. J Neurooncol; 2006 Feb;76(3):299-306
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sphenoid sinus neoplasms: a report of four cases with common clinical presentation treated with transsphenoidal surgery and adjuvant therapies.
  • BACKGROUND: Primary neoplasms of the sphenoid sinus are a rare occurrence, accounting for approximately 1-2% of all paranasal sinus tumors.
  • METHODS: Four patients with sphenoid sinus neoplasms were identified (1%), all treated during the year 2003.
  • Two patients presented with unilateral abducens cranial nerve (CN) palsies; one had trigeminal facial numbness and dizziness; another had headache, epistaxis, and partial third and fourth CN palsies.
  • Cavernous sinus invasion was present in all four cases, including one patient with tumor in the ethmoid sinus and intra-tumoral hemorrhage.
  • All patients underwent subtotal tumor removal via an endonasal transsphenoidal route.
  • Tumor histology included neuroendocrine carcinoma, sinonasal undifferentiated carcinoma, mucoepidermoid carcinoma, and giant cell tumor.
  • Metastatic work-ups were negative in all patients, and all received fractionated stereotactic radiotherapy; three received chemotherapy.
  • One patient required a second endonasal tumor debulking 15 months after the first for new visual loss that then resolved.
  • Their aggressive nature warrants a multimodality treatment plan including surgical debulking, radiotherapy, and chemotherapy in some cases.
  • [MeSH-major] Neurosurgical Procedures. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / therapy. Sphenoid Sinus / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma / therapy. Carcinoma, Giant Cell / metabolism. Carcinoma, Giant Cell / pathology. Carcinoma, Giant Cell / therapy. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Mucoepidermoid / therapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2002 Sep;51(3):699-705; discussion 705-7 [12188948.001]
  • [Cites] Head Neck Surg. 1984 Jan-Feb;6(3):761-76 [6319335.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):371-6 [11859210.001]
  • [Cites] Laryngoscope. 1989 Jul;99(7 Pt 1):716-20 [2747395.001]
  • [Cites] Laryngoscope. 1963 May;73:537-46 [14011951.001]
  • [Cites] Cephalalgia. 1988 Dec;8(4):229-36 [3219724.001]
  • [Cites] Laryngoscope. 1997 Dec;107(12 Pt 1):1590-5 [9396670.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jan;14 (1):11-22 [3335447.001]
  • [Cites] Yonsei Med J. 1988;29(3):209-18 [3057747.001]
  • [Cites] Head Neck. 1996 Mar-Apr;18(2):160-5; discussion 166 [8647682.001]
  • [Cites] Neurosurgery. 1993 Oct;33(4):602-8; discussion 608-9 [8232799.001]
  • [Cites] J Neurosurg. 1981 Aug;55(2):187-93 [7252541.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1179-87 [12973841.001]
  • [Cites] Laryngoscope. 1973 Aug;83(8):1252-65 [4758128.001]
  • [Cites] Pituitary. 2002;5(4):261-5 [14558675.001]
  • [Cites] World J Surg. 2003 Jul;27(7):849-55 [14509518.001]
  • [Cites] Minim Invasive Neurosurg. 1998 Jun;41(2):66-73 [9651913.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):663-72 [12152781.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):581-9 [1503031.001]
  • [Cites] J Otolaryngol. 1978 Oct;7(5):379-88 [105151.001]
  • [Cites] Arch Otolaryngol. 1978 Oct;104(10):585-7 [697636.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Jul;122(7):765-8 [8663951.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1084-91; discussion 1091-2 [10807240.001]
  • [Cites] Otolaryngol Head Neck Surg. 1990 Jun;102(6):709-16 [2115658.001]
  • [Cites] Eur J Pediatr. 1996 Aug;155(8):717-9 [8839732.001]
  • [Cites] J Otolaryngol. 1990 Apr;19(2):122-9 [2348505.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Head Neck. 1991 May-Jun;13(3):208-12 [2037472.001]
  • [Cites] Med J Aust. 2000 Nov 20;173(10):548-9 [11194741.001]
  • [Cites] Neuroradiology. 1998 Oct;40(10 ):651-5 [9833894.001]
  • [Cites] Brain. 1984 Sep;107 ( Pt 3):855-70 [6478180.001]
  • [Cites] J Craniofac Surg. 1995 Jan;6(1):15-23 [8601000.001]
  • [Cites] J Neurosurg Sci. 1999 Mar;43(1):25-36 [10494663.001]
  • [Cites] Head Neck. 2002 Sep;24(9):821-9 [12211046.001]
  • [Cites] Br J Neurosurg. 1994;8(1):51-5 [8011194.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 May;259(5):266-8 [12107531.001]
  • [Cites] Am J Otolaryngol. 1995 Mar-Apr;16(2):109-14 [7793504.001]
  • [Cites] J Neurosurg. 2003 Feb;98(2):350-8 [12593622.001]
  • [Cites] Pathology (Phila). 1996;3(2):513-34 [8795833.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Jan;120(1):19-25 [8274251.001]
  • [Cites] Am J Emerg Med. 2001 Jan;19(1):88-90 [11146033.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):913-5; discussion 915-6 [9574657.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):367-72 [12598339.001]
  • [Cites] Neurosurgery. 2003 Nov;53(5):1126-35; discussion 1135-7 [14580279.001]
  • [Cites] Cancer. 1977 Dec;40(6):3038-41 [412586.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):1964-9 [12439163.001]
  • [Cites] J Laryngol Otol. 1995 Oct;109(10):951-5 [7499947.001]
  • (PMID = 16163447.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Marcus KJ, Dutton SC, Barnes P, Coleman CN, Pomeroy SL, Goumnerova L, Billett AL, Kieran M, Tarbell NJ: A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys; 2003 Apr 1;55(5):1182-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To determine the toxicity and maximum tolerated dose of etanidazole administered concurrently with hyperfractionated radiation therapy (HRT) for children with brainstem glioma.
  • All patients had MRI confirmation of diffuse pontine glioma and signs/symptoms of cranial nerve deficit, ataxia, or long tract signs of <6 months' duration.
  • Patients (median age: 8.5 years; 11 males, 7 females) received HRT to the tumor volume plus a 2-cm margin with parallel-opposed 6-15-MV photons.
  • The total dose was 66 Gy in 44 fractions (1.5 Gy b.i.d., with at least 6 h between fractions) for the first 3 patients and 63 Gy in 42 fractions for the subsequent 15 patients.
  • The median survival from the start of treatment was 8.5 months (range: 3-58 months).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Stem Neoplasms / radiotherapy. Cranial Irradiation. Dose Fractionation. Etanidazole / therapeutic use. Glioma / radiotherapy. Radiation-Sensitizing Agents / therapeutic use. Radiotherapy, High-Energy
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Child. Child, Preschool. Combined Modality Therapy. Dose-Response Relationship, Radiation. Drug Administration Schedule. Female. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans. Male. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12654425.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; 30DKA3Q1HL / Etanidazole
  •  go-up   go-down


22. Massimino M, Giangaspero F, Garrè ML, Genitori L, Perilongo G, Collini P, Riva D, Valentini L, Scarzello G, Poggi G, Spreafico F, Peretta P, Mascarin M, Modena P, Sozzi G, Bedini N, Biassoni V, Urgesi A, Balestrini MR, Finocchiaro G, Sandri A, Gandola L, AIEOP Neuro-Oncology Group: Salvage treatment for childhood ependymoma after surgery only: Pitfalls of omitting "at once" adjuvant treatment. Int J Radiat Oncol Biol Phys; 2006 Aug 1;65(5):1440-5
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage treatment for childhood ependymoma after surgery only: Pitfalls of omitting "at once" adjuvant treatment.
  • PURPOSE: To discuss the results obtained by giving adjuvant treatment for childhood ependymoma (EPD) at relapse after complete surgery only.
  • METHODS AND MATERIALS: Between 1993 and 2002, 63 children older than 3 years old entered the first Italian Association for Pediatric Hematology and Oncology protocol for EPD (group A), and another 14 patients were referred after relapsing after more tumor excisions only (group B).
  • RESULTS: Mean time to first local progression in group B had been 14 months.
  • Tumors originated in the posterior fossa (PF) in 10 children and were supratentorial (ST) in 4; 11 had first been completely excised (NED) and 3 had residual disease (ED).
  • Eight children were referred NED and 6 ED after two or more operations, 5 had cranial nerve palsy, 1 had recurrent meningitis, and 2 had persistent hydrocephalus.
  • All received radiotherapy (RT) to tumor bed and 5 also had pre-RT chemotherapy.
  • Considering only PF tumors and setting time 0 as at the last surgery for group B, progression-free survival and overall survival were 32% and 50% for group B and 52% (p < 0.20)/70% (p < 0.29) for the 46 patients in group A with PF tumors.
  • CONCLUSIONS: Relapsers after surgery only, especially if with PF-EPD, do worse than those treated after first diagnosis; subsequent surgery for tumor relapse has severe neurologic sequelae.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Ependymoma / radiotherapy. Salvage Therapy / methods
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Humans. Neoplasm, Residual. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16863927.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Verhelst J, Abs R: Hyperprolactinemia: pathophysiology and management. Treat Endocrinol; 2003;2(1):23-32
Genetic Alliance. consumer health - Galactorrhoea-Hyperprolactinaemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • If serum prolactin levels are above 200 microg/L, a prolactin-secreting pituitary adenoma (prolactinoma) is the underlying cause, but if levels are lower, differential diagnoses include the intake of various drugs, compression of the pituitary stalk by other pathology, hypothyroidism, renal failure, cirrhosis, chest wall lesions, or idiopathic hyperprolactinemia.
  • When a pituitary tumor is present, patients often have pressure symptoms in addition to endocrine dysfunction, such as headaches, visual field defects, or cranial nerve deficits.
  • The large majority of patients with prolactinomas, both micro- and macroprolactinomas, can be successfully treated with dopaminergic drugs as first-line treatment, with normalization of prolactin secretion and gonadal function, and with significant tumor shrinkage in a high percentage of cases.
  • Surgical resection of the prolactinoma is the option for patients who may refuse or do not respond to long-term pharmacological therapy.
  • In patients with asymptomatic microprolactinoma no treatment needs to be given and a regular follow-up with serial prolactin measurements and pituitary imaging should be organized.
  • When comparing the plasma half-life, efficacy and tolerability of these drugs, cabergoline seems to have the most favorable profile, followed by quinagolide.
  • Ifprolactin levels are well controlled with dopamine agonist therapy, gradual tapering of the dose to the lowest effective amount is recommended, and in a number of cases medication can be stopped after several years.
  • Once pregnant, dopamine agonist therapy should be immediately stopped, unless growth of a macroprolactinoma is likely or pressure symptoms occur.
  • At our institution patients with symptomatic prolactinomas, both micro- and macroadenomas, are treated with cabergoline as the first-line aproach.
  • In the small group of patients who do not respond to this treatment, or who refuse long-term therapy, surgery is offered.
  • Radiotherapy is given if both pharmacologic therapy and surgery fail.
  • [MeSH-major] Hyperprolactinemia / physiopathology. Hyperprolactinemia / therapy
  • [MeSH-minor] Bromocriptine / therapeutic use. Dopamine Agonists / therapeutic use. Ergolines / therapeutic use. Estrogens / therapeutic use. Female. Humans. Male. Pergolide / therapeutic use. Pituitary Neoplasms. Pregnancy. Prolactin / blood. Prolactin / physiology. Prolactinoma. Radiotherapy. Surgical Procedures, Operative

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15871552.001).
  • [ISSN] 1175-6349
  • [Journal-full-title] Treatments in endocrinology
  • [ISO-abbreviation] Treat Endocrinol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Ergolines; 0 / Estrogens; 24MJ822NZ9 / Pergolide; 3A64E3G5ZO / Bromocriptine; 9002-62-4 / Prolactin; LL60K9J05T / cabergoline
  • [Number-of-references] 60
  •  go-up   go-down


24. Pamuk ON, Harmandar F, Cakir N: The development of trigeminal neuralgia related to auricular chondritis in a patient with rheumatoid arthritis-relapsing polychondritis and its treatment with etanercept. Description of the first case. Clin Exp Rheumatol; 2009 Jan-Feb;27(1):128-9
Hazardous Substances Data Bank. Etanercept .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The development of trigeminal neuralgia related to auricular chondritis in a patient with rheumatoid arthritis-relapsing polychondritis and its treatment with etanercept. Description of the first case.
  • Cranial neuropathy is an uncommon manifestation of relapsing polychondritis (RPC).
  • Optic neuropathy is the most common type of cranial nerve involvement in RPC.
  • Cranial MRI and MRI angiography of the brain did not show any pathology.
  • The patient partially responded to RA therapy; and carbamazepine and etanercept were administered.
  • We presume that the TN was caused by compression of the trigeminal nerve from inflammation or ischemia secondary to vasculitis.
  • [MeSH-major] Arthritis, Rheumatoid / complications. Immunoglobulin G / therapeutic use. Immunologic Factors / therapeutic use. Polychondritis, Relapsing / drug therapy. Receptors, Tumor Necrosis Factor / therapeutic use. Trigeminal Neuralgia / drug therapy


25. Schöfl C, Schöfl-Siegert B, Karstens JH, Bremer M, Lenarz T, Cuarezma JS, Samii M, von zur Mühlen A, Brabant G: Falsely low serum prolactin in two cases of invasive macroprolactinoma. Pituitary; 2002;5(4):261-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis of tumors at the base of the skull comprises meningiomas, neurinomas, gliomas, metastatic carcinomas, chordomas, epidermoids, and pituitary adenomas.
  • About half of the pituitary adenomas are prolactinomas which are unique in a sense that medical therapy causes rapid tumor shrinkage and symptomatic improvement.
  • We report on two patients in which the diagnosis of an invasive macroprolactinoma was masked by apparently low prolactin levels caused by a high-dose hook effect in the chemiluminometric assay.
  • The first case a 49 year old male with impairment of hearing on the left side was presented in the Department of Otorhinolaryngology.
  • A massive invasively growing tumor was demonstrated on a cranial MRI.
  • The patient underwent debulking surgery, occipitocervical fusion because of destruction of the first cervical vertebra and subsequent irradiation.
  • The histopathological diagnosis was invasive prolactinoma.
  • Dopamine agonist therapy was initiated under which PRL levels declined in parallel with tumor size.
  • Cranial MRI showed a large tumor at the base of the skull.
  • Based on a transnasal biopsy, the preliminary diagnosis was a poorly differentiated carcinoma for which emergency irradiation was performed.
  • Hydrocortisone was substituted and dopamine agonist therapy was started because of moderate hyperprolactinemia.
  • The final histopathological diagnosis was invasive prolactinoma.
  • Under dopamine agonist therapy, PRL declined to normal values, tumor size decreased and cranial nerve palsies disappeared.
  • This avoids unnecessary aggressive and dangerous treatment like surgery or radiotherapy in cases where pharmacological treatment may be the choice.
  • [MeSH-major] Pituitary Neoplasms / blood. Prolactin / blood. Prolactinoma / blood
  • [MeSH-minor] Adult. Dopamine Agonists / therapeutic use. Ergolines / therapeutic use. False Negative Reactions. Headache / etiology. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Pituitary Function Tests. Skull Base Neoplasms / blood. Skull Base Neoplasms / drug therapy. Skull Base Neoplasms / pathology. Vision Disorders / etiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 1992 May;13(2):220-40 [1352243.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Mar;44(3):305-9 [8729527.001]
  • [Cites] J Clin Endocrinol Metab. 2000 May;85(5):1789-93 [10843153.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):804-12 [9024719.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2381-5 [9253304.001]
  • [Cites] N Engl J Med. 1985 Sep 12;313(11):656-9 [4022058.001]
  • [Cites] Arch Intern Med. 1993 Sep 27;153(18):2165, 2168 [8379808.001]
  • [Cites] Clin Endocrinol (Oxf). 1991 Mar;34(3):231-5 [2036731.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):913-5; discussion 915-6 [9574657.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jul;84(7):2518-22 [10404830.001]
  • (PMID = 14558675.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Ergolines; 9002-62-4 / Prolactin; LL60K9J05T / cabergoline
  •  go-up   go-down






Advertisement